Aceas Abivertinib is a late stage drug that has shown positive clinical trial results in non-small cell lung cancer and B-Cell Lymphoma. Earlier this month, the company announced completion of the Acea Therapeutics acquisition. The drugmaker said it had responded to the U.S. agencys request for additional details on the benefit-risk profile of the drug, adding the FDA would require additional time for a full review of the application. The drugmaker said it had responded to the U.S. agency's request for additional details on the benefit-risk profile of the drug, adding the FDA would require additional time for a full review of the application. If successful, Sorrento will look for regulatory approvals in other countries as well.
Drugs are hard to make.
( z0 hard :ARG1 ( z1 make :ARG1 ( z2 drug ) ) )
(z0 / hard-02
    :ARG1 (z1 / make-01
              :ARG1 (z2 / drug)))
Drugs are hard to make .
z0 :ARG1 z1
z1 :ARG1 z2